期刊
EXPERT REVIEW OF PROTEOMICS
卷 18, 期 9, 页码 767-780出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14789450.2021.1992276
关键词
Adaptive transfer; biomarker; cancer; CAR-T cell therapy; immunotherapy; T-cell therapy; multiplexed analysis; precision medicine
资金
- U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute [R01CA168814]
- U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute [R21HL139934]
- National Institute of Health [T32AI132164]
Cancer immunotherapy, particularly CAR-T cell therapy, has shown rapid advancement, but the validation and standardization of biomarkers for efficacy and toxicity remain challenges. Further expansion of biomarker research could lead to improved precision medicine in understanding patient responses and risks.
Introduction Cancer immunotherapy is a rapidly growing field with exponential advancement in engineered immune cell-based therapies. For instance, an engineered chimeric antigen receptor (CAR) can be introduced in T-cells or other immune cells and adoptively transferred to target and kill cancer cells in hematologic malignancies or solid tumors. The first CAR-T-cell (CAR-T) therapy has been developed against CD19, a B-cell marker expressed on lymphoma and lymphoblastic leukemia. To allow for personalized treatment, proteomics approaches could provide insights into biomarkers for CAR-T therapy efficacy and toxicity. Areas Covered We researched the most recent technology methods of biomarker evaluation used in the laboratory and clinical setting. Publications of CAR-T biomarkers were then systematically reviewed to provide a narrative of the most validated biomarkers of CAR-T efficacy and toxicity. Examples of biomarkers include CAR-T functionality and phenotype as well as interleukin-6 and other cytokines. Expert Commentary Biomarkers of CAR-T efficacy and toxicity have been identified, but still need to be validated and standardized across institutions. Moreover, few are used in the clinical setting due to limitations in real-time technology. Expansion of biomarker research could provide better understanding of patient response and risk of life-threatening side effects with potential for improved precision medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据